[
1. Cusa BV, Sagud M, Rados I. The role of dehydroepiandrosterone (DHEA) in schizophrenia. Psychiatr Danub. 2016; 28(1): 30-3.
]Search in Google Scholar
[
2. Misiak B, Piotrowski P, Chec M, et al. Cortisol and dehydroepiandrosterone sulfate in patients with schizophrenia spectrum disorders with respect to cognitive performance. Compr Psychoneuroendocrinol. 2021; 6. Available from: https://dou.org/10.1016/j.cpnec.2021.10004110.1016/j.cpnec.2021.100041
]Search in Google Scholar
[
3. Nuechterlein KH, Dawson ME, Ventura J, et al. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand. 1994; 89: 58-64.10.1111/j.1600-0447.1994.tb05867.x
]Search in Google Scholar
[
4. Piotrowski P, Rymaszewska J, Stanczykiewicz B, et al. Stress coping strategies and their clinical correlates in patients with psychosis at various stages of illness: a case-control study. Early Interv Psychiatr. 2019; 4: 559-67.
]Search in Google Scholar
[
5. Wambua GN, Kilian S, Ntlantsana V, et al. The association between resilience and psychosocial functioning in schizophrenia: a systematic review and meta-analysis. Psychiatr Res. 2020; 293:113374. 10.1016/j.psychres.2020.11337410.1016/j.psychres.2020.113374
]Search in Google Scholar
[
6. Gallagher P, Ritsner MS. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes: Metabolic and Peripheral Biomarkers. Can the Cortisol to DHEA Molar Ratio be Used as a Peripheral Biomarker for Schizophrenia and Mood Disorders? Springer. 2009; pp.27-45.10.1007/978-1-4020-9838-3_3
]Search in Google Scholar
[
7. Morfin R. DHEA and the brain. Taylor and Francis, London and New York. 2002.10.1201/b12558
]Search in Google Scholar
[
8. Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neuro-steroids. J Endocrinol. 1996; 150:221-39.
]Search in Google Scholar
[
9. Maninger N, Wolkowitz OM, Reus VI, et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA Sulfate (DHEAS). Front Neuroendocrinol. 2009; 30(1):65-91.10.1016/j.yfrne.2008.11.002
]Search in Google Scholar
[
10. Wen S, Dong K, Onolfo JP, et al. Treatment with dehydroepiandrosterone sulfate increases NMDA receptor in hippocampus and cortex. Eur J Pharmacol. 2001; 430:373-4.10.1016/S0014-2999(01)01383-8
]Search in Google Scholar
[
11. Compagnone NA, Melton SH. Neurosteroids: biosynthesis and function of these novel neuro-modulators. Front Neuroendocrinol. 2000; 21:1-56.10.1006/frne.1999.018810662535
]Search in Google Scholar
[
12. Singh M, Solanki RK, Bagaria B, et al. Hypothalamic-pituitary-adrenal (HPA) axis functioning among patients with schizophrenia: A cross sectional comparative study. J Psychiatry. 2015; 18(1):14-65.
]Search in Google Scholar
[
13. Erjavec G, Uzun S, Perkovic M, et al. Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 77:228-35.10.1016/j.pnpbp.2017.04.03228461252
]Search in Google Scholar
[
14. di Michele F, Caltagirone C, Bonaviri G, et al. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res. 2005; 39:267-73.10.1016/j.jpsychires.2004.08.00515725425
]Search in Google Scholar
[
15. Strous RD, Maayan R, Lapidus R, et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res. 2004; 71:427-34.10.1016/j.schres.2004.03.00515474914
]Search in Google Scholar
[
16. Ritsner M, Maayan R, Gibel A, et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004; 14:267-73.10.1016/j.euroneuro.2003.09.00315163435
]Search in Google Scholar
[
17. Misiak B, Stramecki F, Gaweda L, et al. Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Mol Neurobiol. 2018; 55(6): 5075-100.10.1007/s12035-017-0708-y594825728822116
]Search in Google Scholar
[
18. Zhang XY, Zhou DF, Cao LY, et al. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacol. 2005; 30(8):1532-8.10.1038/sj.npp.130075615886721
]Search in Google Scholar
[
19. Gorobets LN, Litvinov AV, Bulanov VS. The indices of cortisol and dehydroepiandrosterone sulfate as potential biomarkers of the efficacy of antipsychotic therapy in patients with the first psychotic episode. Современная терапия психических расстройств. 2018; 1:11-19.
]Search in Google Scholar
[
20. Mondelli V, Ciufolini S, Murri MB, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophrenia Bull. 2015; 41(5):1162-70.10.1093/schbul/sbv028453563725829375
]Search in Google Scholar
[
21. Yıldırım O, Dogan O, Semiz M, et al. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci. 2011; 65:584–91.10.1111/j.1440-1819.2011.02252.x21895860
]Search in Google Scholar
[
22. Ryan MC, Sharifi N, Condren R, et al. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrino. 2004; 29:1065-70.10.1016/j.psyneuen.2003.08.01115219658
]Search in Google Scholar
[
23. Gallagher P, Watson S, Smith MS, et al. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res. 2007; 90(1-3): 258-65.10.1016/j.schres.2006.11.02017222537
]Search in Google Scholar
[
24. Hori H, Teraishi T, Sasayama D, et al. Elevated cortisol level and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test. The Open Neuropsychopharmacology. 2012; 5:18-24.10.2174/1876523801205010018
]Search in Google Scholar
[
25. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010; 119(1-3):131-7.10.1016/j.schres.2010.01.03320226630
]Search in Google Scholar
[
26. Yilmaz N, Herken H, Cicek HK, et al. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007; 16(2):137-41.10.1159/000098367
]Search in Google Scholar
[
27. Boiko AS, Mednova IA, Kornetova EG, et al. Cortisol and DHEAS related to metabolic syndrome in patients with schizophrenia. Neuro-psych Dis Treat. 2020; 16:1051-8.10.2147/NDT.S247161
]Search in Google Scholar
[
28. Bulut SD, Bulut S, Gundogmus AG, et al. Serum DHEA-S, testosterone and cortisol levels in female patients with schizophenia. Endocr Metab Immune Disord Drug Targets. 2018; 18(4):348-54.10.2174/1871530318666180212102128
]Search in Google Scholar
[
29. Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitary adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:935–8.10.1016/S0278-5846(02)00208-7
]Search in Google Scholar
[
30. Taherianfard M, Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci. 2004; 58(1):3-9.
]Search in Google Scholar
[
31. Wilczynski KM, Tobolska D, Lorek M, et al. Comparison of cortisol levels in patients with schizophrenia and in healthy controls. Eur Psychiat. 2017; 41:818.10.1016/j.eurpsy.2017.01.1593
]Search in Google Scholar
[
32. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response in patients with schizophrenia. Neuropsychopharmacol. 2001; 24:278-90.10.1016/S0893-133X(00)00201-3
]Search in Google Scholar
[
33. Misiak B, Frydecka D, Oska O, et al. Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis. Psychoneuroendocrino. 2018; 89: 92-102.10.1016/j.psyneuen.2018.01.00729334627
]Search in Google Scholar
[
34. Beyazyüz M, Albayrak Y, Beyazyüz E, et al. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014; 10: 687–93.
]Search in Google Scholar
[
35. Solanki RK, Sharma P, Tyagi A, et al. Serum levels of neuroactive steroids in first-episode antipsychotic-naïve schizophrenic patients and its correlation with aggression: a case-control study. East Asian Arch Psychiatry. 2017; 27:79-84.
]Search in Google Scholar
[
36. Ji E, Weickert CS, Tyson TP, et al. Cortisol-dehydroepiandrosterone ratios are inversely associated with hippocampal and prefrontal brain volume in schizophrenia. Psychoneuroendrocrinol. 2021; 123:104916.10.1016/j.psyneuen.2020.10491633169678
]Search in Google Scholar
[
37. Ritsner M, Gibel A, Ram E, et al. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. Eur Neuropsychopharmacol. 2006; 16:137-46.10.1016/j.euroneuro.2005.07.00716139994
]Search in Google Scholar
[
38. Ritsner M, Gibel A, Maayan R, et al. Cortisol/ Dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacol. 2005; 30:1913-22.10.1038/sj.npp.130074715870835
]Search in Google Scholar
[
39. Peng R, Li Y. Association among serum cortisol, dehydroepiandrosterone-sulfate levels and psychiatric symptoms in men with chronic schizophrenia. Compr Psychiatry. 2017; 76:113-8.10.1016/j.comppsych.2017.03.01128482249
]Search in Google Scholar
